Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Net Margin for 6 consecutive years, with 10189.51% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin fell 597759.0% year-over-year to 10189.51%, compared with a TTM value of 12016.77% through Sep 2025, up 325552.0%, and an annual FY2024 reading of 408.73%, up 874925.0% over the prior year.
  • Net Margin was 10189.51% for Q3 2025 at Barinthus Biotherapeutics, up from 2112600.0% in the prior quarter.
  • Across five years, Net Margin topped out at 1683700.0% in Q4 2021 and bottomed at 2112600.0% in Q2 2025.
  • Average Net Margin over 5 years is 18489.21%, with a median of 5216.4% recorded in 2024.
  • The sharpest move saw Net Margin crashed -168402775bps in 2022, then skyrocketed 24732775bps in 2023.
  • Year by year, Net Margin stood at 1683700.0% in 2021, then plummeted by -100bps to 327.75% in 2022, then skyrocketed by 75462bps to 247000.0% in 2023, then plummeted by -105bps to 11971.51% in 2024, then grew by 15bps to 10189.51% in 2025.
  • Business Quant data shows Net Margin for BRNS at 10189.51% in Q3 2025, 2112600.0% in Q2 2025, and 6220.89% in Q1 2025.